S&P lowers NBTY credit rating
This article was originally published in The Tan Sheet
Executive Summary
Standard & Poor's lowers the vitamin and supplement maker's credit rating from 'BB' to 'B+' in light of the Carlyle Group's planned acquisiton. The change "reflects weakened credit measures" from Carlyle's proposed capital structure for NBTY, including about $2 billion in additional debt, analyst Jacqueline Hui said in an Aug. 26 release. But the rating service deemed NBTY "stable," saying the company likely will "maintain pro forma credit metrics in line with the current rating over the near term." NBTY remains in a strong market position, but the supplement market is highly competitive, S&P noted. Carlyle announced its $3.8 billion acqusition July 15 (1"The Tan Sheet" July 19, 2010)
You may also be interested in...
Carlyle Group's $3.8B Bid For NBTY Could Face Competition
The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Keeping Track: More Rx-To-OTC Switches On Deck After US FDA’s OTC Narcan Approval; Iovance Looks To Bring Cell Therapy To Melanoma
The latest drug development news and highlights form the Pink Sheet’s US FDA Performance Tracker.